🇺🇸 FDA
Patent

US 7951817

Pyridomorphinans, pyridazinomorphinans and use thereof

granted A61PA61P25/00A61P25/04

Quick answer

US patent 7951817 (Pyridomorphinans, pyridazinomorphinans and use thereof) held by The United States of America, as represented by the Department of Health and Human Services expires Mon May 26 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue May 31 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 26 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P25/00, A61P25/04, A61P25/30, A61P25/36